Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 809-812

  Baxter, P A ^a   Thompson, P A ^a   McGuffey, L M ^a   Gibson, B W ^a   Dauser, R C ^a   Nuchtern, J G ^a   Shi, C ^b   Inloes, R ^b   Choy, G ^b   Redkar, S ^b   Blaney, S M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SuperGen Inc   (United States)

Author keywords

CSF penetration; MP470; Pharmacokinetics; Tyrosine kinase inhibitor

Indexed keywords

4 [1]BENZOFURO[3,2 D]PYRIMIDIN 4 YL N (1,3 BENZODIOXOL 5 YLMETHYL)PIPERAZINE 1 CARBOTHIAMIDE; MP 470; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG PENETRATION; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; HALF-LIFE; MACACA MULATTA; MALE; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TANDEM MASS SPECTROMETRY;

EID: 79954438228     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1380-3     Document Type: Article

References (24)

1. MC Heinrich, et al. 2002 Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J Clin Oncol 20 6 1692 1703 11896121 10.1200/JCO.20.6.1692 1:CAS:528: DC%2BD38XivFeit7o%3D (Pubitemid 34260552)
2. S Hirota, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
3. ML Lux, et al. 2000 KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 156 3 791 795 10702394 10.1016/S0002-9440(10)64946-2 1:CAS:528:DC%2BD3cXitVerur0%3D (Pubitemid 30626936)
4. DA Arber R Tamayo LM Weiss 1998 Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders Hum Pathol 29 5 498 504 9596274 10.1016/S0046-8177(98)90066-1 1:STN:280:DyaK1c3lsFOisQ%3D%3D (Pubitemid 28213470)
5. Q Tian, et al. 1999 Activating c-kit gene mutations in human germ cell tumors Am J Pathol 154 6 1643 1647 10362788 10.1016/S0002-9440(10)65419-3 1:CAS:528:DyaK1MXjvFGrtrc%3D (Pubitemid 29262845)
6. A Beghini, et al. 2000 C-kit mutations in core binding factor leukemias Blood 95 2 726 727 10660321 1:STN:280:DC%2BD3c7itlSmtA%3D%3D (Pubitemid 30041697)
7. BE Smithey AS Pappo DA Hill 2002 C-kit expression in pediatric solid tumors: a comparative immunohistochemical study Am J Surg Pathol 26 4 486 492 11914627 10.1097/00000478-200204000-00011 (Pubitemid 34280122)
8. GB Qiao, et al. 2005 High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients Br J Cancer 93 1 137 143 15956972 10.1038/sj.bjc.6602665 1:CAS:528:DC%2BD2MXlsl2itLY%3D (Pubitemid 41076262)
9. LT Hansen, et al. 2003 The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer Int J Cancer 105 4 472 479 12712436 10.1002/ijc.11106 1:CAS:528:DC%2BD3sXktlOqsLw%3D (Pubitemid 36578549)
10. W Henning HW Sturzbecher 2003 Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance Toxicology 193 1-2 91 109 14599770 10.1016/S0300-483X(03)00291-9 1:CAS:528:DC%2BD3sXos1KhsLc%3D (Pubitemid 37340146)
11. NRC (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
12. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York
13. D'Argenio D, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles
14. Kissling C et al (2008) Effects of food on single-dose pharmacokinetics of oral MP-470 capsules (abstract). In: EJC Supplements-20th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics, Oct 21-24, Geneva Switzerland, p 134 Abstract nr 426
15. W Qi, et al. 2009 MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer BMC Cancer 9 1 142 19432987 10.1186/1471-2407-9-142
16. Tolcher A et al (2009) Clinical responses to MP-470, an oral RAD51 inhibitor, in combination with standard of care doublet chemotherapy, in patients with SCLC and NE malignancies: a phase 1 case series (Abstract). In: Scientific Programme, IASLC: 13th world conference on lung cancer, San Francisco CA, July 13-August 4, 2009, p 101 abstract nr 7936
17. AS Advani 2005 FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications Curr Pharm Des 11 26 3449 3457 16250847 10.2174/138161205774370807 1:CAS:528:DC%2BD2MXhtVWrs7vF (Pubitemid 41300770)
18. CL Corless, et al. 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 23 5357 5364 15928335 10.1200/JCO.2005.14.068 1:CAS:528:DC%2BD2MXpslOrtLY%3D (Pubitemid 46206989)
19. A Machens K Lorenz H Dralle 2009 Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities J Intern Med 266 1 114 125 19522830 10.1111/j.1365-2796.2009.02113.x 1:CAS:528:DC%2BD1MXptVaqtb8%3D
20. C Lanzi, et al. 2009 Targeting RET for thyroid cancer therapy Biochem Pharmacol 77 3 297 309 19028457 10.1016/j.bcp.2008.10.033 1:CAS:528: DC%2BD1MXhtFCjur0%3D
21. WK You DM McDonald 2008 The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis BMB Rep 41 12 833 839 19123972 1:CAS:528:DC%2BD1MXpt1Slsg%3D%3D
22. AW Ke, et al. 2009 Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma Hepatology 49 2 491 503 19065669 10.1002/hep.22639 1:CAS:528:DC%2BD1MXivFWhtrc%3D
23. JJ Heimans, et al. 1994 Paclitaxel (Taxol) concentrations in brain tumor tissue Ann Oncol 5 10 951 953 7696168 1:STN:280:DyaK2M3htVWmsA%3D%3D
24. Welsh J et al (2009) The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. J Radiat Oncol 4(69). doi: 10.1186/1748-717X-4-69